Articles

Immunotherapy for prostate cancer: Does it work?

BJMO - volume 18, issue 4, june

D. Schrijvers MD, PhD

SUMMARY

Immunotherapy has changed the treatment landscape for many tumour types. In patients with prostate cancer, different types of immunotherapy such as cellular, dendritic cell, peptide, viral, antigen-loaded dendritic cell or antigen-presenting cell vaccines and checkpoint inhibitors have been tested in randomised phase III trials as a single agent or in combination with other treatment modalities. Only one specific antigen-loaded dendritic cell (sipuleucel-T) has shown some benefit in terms of overall survival in this patient population. Newer treatments, such as bi-specific T-cell engagers or chimeric antigen receptor T-cell therapy, are being tested in early clinical trials in different subsets of patients with prostate cancer. Monoclonal antibodies, linked to radioactive isotopes, have been successfully used in the diagnosis and treatment of prostate cancer and are mentioned briefly. This review focuses on the role of cellular-based immunotherapy in patients with prostate cancer.

(BELG J MED ONCOL 2024;18(4):152–9)

Read more

Impact of treatment delays in patients with head and neck cancer

BJMO - volume 18, issue 2, march 2024

D. Schrijvers MD, PhD, S. Mignon MD, M. Brands MD, S. van Roy MD, S. De Schepper MD, N. Van Bruaene MD, D. Nevens MD, PhD, N. Meireson MD

SUMMARY

Head and neck cancer is a complex cancer that involves multiple disciplines (surgery, radiotherapy, systemic therapy). The timely start of surgery and radiotherapy is of utmost importance since the time between the start of treatment is related to overall survival. A delay in surgery increases overall mortality by 6%, while a delay in radiotherapy increases overall mortality by 9%. In this article, the importance of a short time to start treatment in patients with head and neck cancer is discussed.

(BELG J MED ONCOL 2024;18(2):46–8)

Read more

A rare tumour of the lacrimal gland: Immunoglobulin G4-related pseudo tumour

BJMO - volume 18, issue 1, february 2024

D. Schrijvers MD, PhD, L. Velthof MD, K. De Boeck MD, M. Al Saddi MD, V. De Groot MD, PhD

SUMMARY

This case report describes a patient with a lacrimal tumour and distant bone lesions. The diagnosis of an IgG4-related pseudo tumour of the lacrimal gland with involvement of the skeleton was made. A review of lacrimal gland lesions and IgG4-related disease is given. The oncologist should be aware of this entity and it should be included in the differential diagnosis of lacrimal gland lesions.

(Belg J Med Oncol 2024;18(1):24–8)

Read more

A subungual glomus tumour in a patient with a previous history of testicular cancer

BJMO - volume 17, issue 7, november 2023

M. De Wit MD, L-A-F. Clifton MD, E. Beuckelaers MD, J. Desimpelaere MD, D. Schrijvers MD, PhD

SUMMARY

This article presents the case of a 35-year-old patient with a glomus tumour in the fourth digit of the right hand. The patient had a history of a bilateral embryonal testicular carcinoma, which was treated with surgery and chemotherapy. The initial complaints consisted of pain in all the fingers on the right hand, suspected of Raynaud phenomenon. Finally, the diagnosis was made clinically and through magnetic resonance imaging. He underwent surgery to remove the tumour, and the diagnosis was pathologically confirmed. The treatment was curative, and the complaint of pain resolved.

(Belg J Med Oncol 2023;17(7):264–6)

Read more

Burnout in resident physicians

BJMO - volume 17, issue 3, may 2023

D. Schrijvers MD, PhD

SUMMARY

Burnout is an important consequence of work-related stress. It is observed in 15–40% of resident physicians and has an important influence on their wellbeing, their professional career, and their patient-doctor relationship. Different interventions at the organisational, interpersonal and personal levels can be performed to prevent the development of burnout.

(BELG J MED ONCOL 2023;17(3):85–7)

Read more

Head and neck cancer: The role of cisplatin

BJMO - volume 17, issue 2, march 2023

D. Schrijvers MD, PhD

SUMMARY

Cisplatin has been the backbone of the treatment of patients with squamous cell carcinoma of the head and neck, both in recurrent/metastatic settings and in patients with locoregional disease. In patients with recurrent/metastatic disease and a combined positivity score (CPS) ≥20, cisplatin can be replaced by pembrolizumab. In patients with locoregional disease and treated with definitive chemoradiation or in the adjuvant setting, the 3-weekly high-dose cisplatin can be replaced by the weekly 40 mg/m2 cisplatin regimen.

(Belg J Med Oncol 2023;17(2):52–7)

Read more

Audits in medical oncology

BJMO - volume 17, issue 1, january 2023

D. Schrijvers MD, PhD

SUMMARY

The quality of oncological care can be ensured by different means, such as graduate and postgraduate education, guidelines, quality labels and audits. Audits in medical oncology departments are not routinely performed and are only used in case of problems. In this article, the introduction of audits in the medical oncology department is advocated, and a strategy to implement this quality improving tool is proposed.

(BELG J MED ONCOL 2023;17(1):19–26)

Read more